Alternative treatment for chemoresistant glioblastoma

 XIAN WANG HTTPS://ORCID.ORG/0000-0002-1501-2544, ZHEYUAN GONG HTTPS://ORCID.ORG/0000-0002-8739-5222, TIANCONG WANG HTTPS://ORCID.ORG/0000-0002-0936-5394, JUNHUI LAW HTTPS://ORCID.ORG/0000-0002-6033-7639, XIN CHEN HTTPS://ORCID.ORG/0000-0001-7620-5975, SIYI WANGGOU, JINTIAN WANG HTTPS://ORCID.ORG/0000-0001-5259-3344, BINBIN YING HTTPS://ORCID.ORG/0000-0001-8529-5036, MICHELLE FRANCISCO HTTPS://ORCID.ORG/0000-0002-4950-3499, [...], AND YU SUN HTTPS://ORCID.ORG/0000-0001-7895-0741 +9 authorsAuthors Info & Affiliations

Abstract

Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Despite multimodal treatment including surgery, radiotherapy, and chemotherapy, median patient survival has remained at ~15 months for decades. This situation demands an outside-the-box treatment approach. Using magnetic carbon nanotubes (mCNTs) and precision magnetic field control, we report a mechanical approach to treat chemoresistant GBM. We show that GBM cells internalize mCNTs, the mobilization of which by rotating magnetic field results in cell death. Spatiotemporally controlled mobilization of intratumorally delivered mCNTs suppresses GBM growth in vivo. Functionalization of mCNTs with anti-CD44 antibody, which recognizes GBM cell surface–enriched antigen CD44, increases mCNT recognition of cancer cells, prolongs mCNT enrichment within the tumor, and enhances therapeutic efficacy. Using mouse models of GBM with upfront or therapy-induced resistance to temozolomide, we show that mCNT treatment is effective in treating chemoresistant GBM. Together, we establish mCNT-based mechanical nanosurgery as a treatment option for GBM.

https://www.science.org/doi/10.1126/sciadv.ade5321